Current phase of trial: Phase 2
Type of MS: Relapsing MS
Find out more about amiselimod
How does amiselimod work?
Amiselimod works in a similar way to the licensed treatment fingolimod. It binds to receptors on immune cells and alters their behaviour, stopping them from damaging myelin.
How is amiselimod taken?
Amiselimod is a tablet taken daily.
This phase 2 trial involved 400 people with relapsing MS, and results were published in October 2016. Researchers found that amiselimod reduced the total number of lesions over 24 weeks, with the higher dose having the biggest effect. Amiselimod also reduced relapse rates at higher doses.
There were no differences reported in adverse events between all amiselimod doses and the placebo group.
What are the side effects of amiselimod?
Information on the side effects of amiselimod is not yet available.
How does amiselimod compare with current treatments?
Amiselimod hasn't been compared with other MS treatments.
When is amiselimod likely to become available?
Phase 2 trial results were published in 2016, and MT Pharma announced that they would continue to develop the treatment.
For amiselimod to be available, it would need to be shown to be safe and effective in phase 3 trials, and go through the licensing process. This is like to take several years.